The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer

Prostate

Volumn 72, Issue 10, 2012, Pages 1093-1103

  Sun, Tong ^a   Yang, Ming ^a   Chen, Shaoyong ^b   Balk, Steven ^b   Pomerantz, Mark ^a   Hsieh, Chen Lin ^a   Brown, Myles ^a   Lee, Gwo Shu Mary ^a   Kantoff, Philip W ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

microRNA; miR 221 222; prostate cancer

Indexed keywords

ANDROGEN; MICRORNA; MICRORNA 15A; MICRORNA 16 1; MICRORNA 203; MICRORNA 221; MICRORNA 222; MICRORNA 23B; MICRORNA 27B; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE;

CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84861576642     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22456     Document Type: Article

References (46)

1. Ahmedin Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59: 1-25.
2. Balk SP, Knudsen KE,. AR, the cell cycle and prostate cancer. Nucl Recept Signal 2008; 6: e001.
3. Messing EM, Manola J, Sarosday M, Wilding G, Crawford ED, Trump D,. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-1788.
4. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-8261.
5. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
6. Mostaghel EA, Nelson PS,. Intracrine androgen metabolism in prostate cancer progression: Mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 2008; 22: 243-258.
7. Pienta KJ, Bradley D,. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1665-1671.
8. Yuan X, Balk SP,. Mechanisma mediating androgen receptor reactivation after castration. Urol Oncol 2009; 27: 36-41.
9. Carthew RW, Sontheimer EJ,. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-655.
10. Bartel DP,. MicroRNAs: Target recognition and regulatory functions. Cell 2009; 136: 215-233.
11. Visone R, Croce CM,. MiRNAs and cancer. Am J Pathol 2009; 174: 1131-1138.
12. Lee YS, Dutta A,. MicroRNAs in cancer. Annu Rev Pathol 2009; 4: 199-227.
13. Negrini M, Nicoloso MS, Calin GA,. MicroRNAs and cancer - New paradigms in molecular oncology. Curr Opin Cell Biol 2009; 21: 470-479.
14. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM,. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
15. Kent OA, Mendell JT,. A small piece in the cancer puzzle: Micrornas as tumor suppressors and oncogenes. Oncogene 2006; 25: 6188-6196.
16. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
17. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR,. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
18. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T,. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-6135.
19. Ozen M, Creighton CJ, Ozdemir M, Ittmann M,. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2007; 27: 1788-1793.
20. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM,. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008; 68: 6162-6170.
21. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, Bartucci M, Muto G, Peschle C, De Maria R,. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271-1277.
22. Sun T, Wang Q, Balk S, Brown M, Lee MG-S, Kantoff P,. The Role of microRNA-221 and -222 in Castration Resistant Prostate Cancer. Cancer Res 2009; 69: 3356-3363.
23. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H,. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumor progression in a new model system. Br J Cancer 1999; 81: 242-251.
24. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML,. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res 2009; 69: 5568-5574.
25. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-2825.
26. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M,. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138: 245-256.
27. Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M,. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007; 27: 380-392.
28. Wang Q, Carroll JS, Brown M,. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 2005; 19: 631-642.
29. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, Nemunaitis J,. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009; 16: 206-216.
30. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K,. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126: 1166-1176.
31. Spahn M, Kneitz S, Scholz C, Stenger N, Thomas Rüdiger T, Ströbel P, Hubertus Riedmiller H, Kneitz B,. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010; 127: 394-403.
32. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM, Condorelli G,. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008; 27: 3845-3855.
33. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, Croce CM,. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009; 16: 498-509.
34. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ,. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008; 283: 31079-31086.
35. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S,. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 283: 29897-29903.
36. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O,. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010; 127: 1785-1794.
37. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP,. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011; 30: 1082-1097.
38. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, Zhi-Fan J, Pei-Yu P, Qing-Yu Z, Chun-Sheng K,. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 2010; 10: 367.
39. Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L, Jia ZF, Yang WD, Wang GX, Jiang T, You YP, Pu PY, Cheng JQ, Kang CS,. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 2010; 9: 229.
40. Zhang C, Zhang J, Zhang A, Wang Y, Han L, You Y, Pu P, Kang C,. PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol 2010; 37: 1621-1626.
41. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L, Negrini M,. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 2009; 15: 5073-5081.
42. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L, Negrini M,. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27: 5651-5661.
43. Medina R, Zaidi SK, Liu CG, Stein JL, van Wijnen AJ, Croce CM, Stein GS,. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 2008; 68: 2773-2780.
44. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, Santoro S, Valtieri M, Calin GA, Liu CG, Sorrentino A, Croce CM, Peschle C,. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005; 102: 18081-18086.
45. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV,. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458: 762-765.
46. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM,. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008; 21: 1156-1167.